Livedoid Pattern in the Abdomen of a Patient with Myelofibrosis: A Quiz
DOI:
https://doi.org/10.2340/actadv.v101.277Keywords:
Reactive angioendotheliomatosis, myelofibrosis, prothrombotic, livedoid patternAbstract
Abstract is missing (Quiz)
Downloads
References
McMenamin MC, Fletcher CD. Reactive angioendotheliomatosis a study of 15 cases demonstrating a wide clinicopathologic spectrum. Am J Surg Pathol 2002; 26: 685-697.
https://doi.org/10.1097/00000478-200206000-00001 DOI: https://doi.org/10.1097/00000478-200206000-00001
Singer C, Mallon D, Auguston B, Lam M, Foster R. Reactive angioendotheliomatosis presenting as livedo racemosa secondary to propylthiouracil. Pathology 2020; 52: 494-496.
https://doi.org/10.1016/j.pathol.2020.03.006 DOI: https://doi.org/10.1016/j.pathol.2020.03.006
Lazova R, Slater C, Scott G. Reactive angioendotheliomatosis. Case report and review of the literature. Am J Dermatopathol 1996; 18: 63-69.
https://doi.org/10.1097/00000372-199602000-00010 DOI: https://doi.org/10.1097/00000372-199602000-00010
Thai K, Barrett W, Kossard S. Reactive angioendotheliomatosis in the setting of antiphospholipid syndrome. Australas J Dermatol 2010; 44: 151-155.
https://doi.org/10.1046/j.1440-0960.2003.00670.x DOI: https://doi.org/10.1046/j.1440-0960.2003.00670.x
Di Filippo Y, Cardot-Leccia N, Long-Mira E, Andreani M, Richez V, Lacour JP, et al. Reactive angioendotheliomatosis revealing a glomerulopathy secondary to a monoclonal gammopathy successfully treated with lenalidomide. J Eur Acad Dermatol Venereol 2021; 35: 115-118.
https://doi.org/10.1111/jdv.16840 DOI: https://doi.org/10.1111/jdv.16840
Mazloom SE, Stallings A, Kyei A. differentiating intralymphatic histiocytosis, intravascular histiocytosis, and subtypes of reactive angioendotheliomatosis: review of clinical and histologic features of all cases reported to date. Am J Dermatopathol 2017; 39: 33-39.
https://doi.org/10.1097/DAD.0000000000000574 DOI: https://doi.org/10.1097/DAD.0000000000000574
Kirke S, Angus B, Kesteven PJ, Calonje E, Simpson N. Localized reactive angioendotheliomatosis. Clin Exp Dermatol 2007; 32: 45-47.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798.
https://doi.org/10.1056/NEJMoa1110556 DOI: https://doi.org/10.1056/NEJMoa1110556
Gangat N, Tefferi A. Myelofibrosis biology and contemporary management. Br J Haematol 2020; 191: 152-170.
https://doi.org/10.1111/bjh.16576 DOI: https://doi.org/10.1111/bjh.16576
Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood 2018; 132: 1561-1567.
https://doi.org/10.1182/blood-2017-04-737445 DOI: https://doi.org/10.1182/blood-2017-04-737445
Perniciaro C, Winkelmann RK, Daoud MS, Su WP. Malignant angioendotheliomatosis is an angiotropic intravascular lymphoma. Immunohistochemical, ultrastructural, and molecular genetics studies. Am J Dermatopathol 1995; 17: 242-248.
https://doi.org/10.1097/00000372-199506000-00005 DOI: https://doi.org/10.1097/00000372-199506000-00005
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Diego Soto-García, Gonzalo Peón, Carlos Álvarez, Carmen Couselo-Rodríguez, Ángelez Flórez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
